$INFU
InfuSystem Holdings, Inc

2023 Q2 Form 10-Q Financial Statement

#000162828023016802 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $31.74M $30.37M
YoY Change 17.35% 13.48%
Cost Of Revenue $15.29M $14.83M
YoY Change 25.96% 30.13%
Gross Profit $16.44M $15.54M
YoY Change 10.34% 1.13%
Gross Profit Margin 51.81% 51.17%
Selling, General & Admin $15.01M $15.29M
YoY Change 7.06% 0.99%
% of Gross Profit 91.31% 98.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.093M $2.955M
YoY Change -9.03% 9.2%
% of Gross Profit 18.81% 19.02%
Operating Expenses $15.19M $15.65M
YoY Change 3.4% -1.54%
Operating Profit $1.248M -$107.0K
YoY Change 502.9% -79.62%
Interest Expense $620.0K $484.0K
YoY Change 97.45% 74.73%
% of Operating Profit 49.68%
Other Income/Expense, Net $2.000K -$35.00K
YoY Change -106.67% 25.0%
Pretax Income $630.0K -$626.0K
YoY Change -559.85% -24.58%
Income Tax $195.0K -$302.0K
% Of Pretax Income 30.95%
Net Earnings $435.0K -$324.0K
YoY Change -365.24% -11.96%
Net Earnings / Revenue 1.37% -1.07%
Basic Earnings Per Share $0.02 -$0.02
Diluted Earnings Per Share $0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 20.93M shares 20.89M shares
Diluted Shares Outstanding 21.60M shares 20.85M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $134.0K $256.0K
YoY Change -56.91% -36.79%
Cash & Equivalents $134.0K $256.0K
Short-Term Investments
Other Short-Term Assets $3.916M $3.752M
YoY Change 102.27% 45.15%
Inventory $5.706M $5.644M
Prepaid Expenses
Receivables $18.87M $18.27M
Other Receivables $0.00 $0.00
Total Short-Term Assets $28.63M $27.92M
YoY Change 24.67% 20.03%
LONG-TERM ASSETS
Property, Plant & Equipment $4.303M $4.391M
YoY Change -0.16% 0.37%
Goodwill $3.710M $3.710M
YoY Change 0.0% 0.0%
Intangibles $7.942M $8.188M
YoY Change -16.48% -19.87%
Long-Term Investments
YoY Change
Other Assets $1.224M $425.0K
YoY Change -21.44% -69.2%
Total Long-Term Assets $74.12M $74.34M
YoY Change -2.28% -0.85%
TOTAL ASSETS
Total Short-Term Assets $28.63M $27.92M
Total Long-Term Assets $74.12M $74.34M
Total Assets $102.7M $102.3M
YoY Change 3.98% 4.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.481M $7.368M
YoY Change -41.9% -10.6%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $12.87M $13.93M
YoY Change -10.8% -0.08%
LONG-TERM LIABILITIES
Long-Term Debt $36.14M $36.39M
YoY Change 7.28% 4.58%
Other Long-Term Liabilities $3.786M $3.684M
YoY Change -10.03% 6.75%
Total Long-Term Liabilities $36.14M $36.39M
YoY Change 7.28% 4.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.87M $13.93M
Total Long-Term Liabilities $36.14M $36.39M
Total Liabilities $52.79M $54.00M
YoY Change 0.9% 3.48%
SHAREHOLDERS EQUITY
Retained Earnings -$59.39M -$59.82M
YoY Change 1.01% 2.65%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.96M $48.26M
YoY Change
Total Liabilities & Shareholders Equity $102.7M $102.3M
YoY Change 3.98% 4.1%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $435.0K -$324.0K
YoY Change -365.24% -11.96%
Depreciation, Depletion And Amortization $3.093M $2.955M
YoY Change -9.03% 9.2%
Cash From Operating Activities $2.452M -$151.0K
YoY Change -54.74% -103.7%
INVESTING ACTIVITIES
Capital Expenditures $3.203M $317.0K
YoY Change -182.21% 78.09%
Acquisitions
YoY Change
Other Investing Activities $864.0K $1.234M
YoY Change -22.51% 27.74%
Cash From Investing Activities -$2.339M -$3.051M
YoY Change -15.89% 42.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -235.0K $3.293M
YoY Change -91.39% -291.9%
NET CHANGE
Cash From Operating Activities 2.452M -$151.0K
Cash From Investing Activities -2.339M -$3.051M
Cash From Financing Activities -235.0K $3.293M
Net Change In Cash -122.0K $91.00K
YoY Change 29.79% -58.45%
FREE CASH FLOW
Cash From Operating Activities $2.452M -$151.0K
Capital Expenditures $3.203M $317.0K
Free Cash Flow -$751.0K -$468.0K
YoY Change -108.06% -112.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001337013
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35020
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
INFUSYSTEM HOLDINGS, INC
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3341405
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3851 West Hamlin Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rochester Hills
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48309
CY2023Q1 dei City Area Code
CityAreaCode
248
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
291-1210
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
INFU
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20931147 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
256000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18266000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16871000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
5644000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
4821000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3752000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2922000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
27918000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24779000 usd
CY2023Q1 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
3042000 usd
CY2022Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
2790000 usd
CY2023Q1 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
38620000 usd
CY2022Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39450000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4391000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4385000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
3710000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3710000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8188000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8436000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4295000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4168000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9989000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
9625000 usd
CY2023Q1 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
1683000 usd
CY2022Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
1965000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
425000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
80000 usd
CY2023Q1 us-gaap Assets
Assets
102261000 usd
CY2022Q4 us-gaap Assets
Assets
99388000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7368000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8341000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6562000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6126000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13930000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14467000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36386000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33157000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3684000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3761000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
54000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
51385000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20931147 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20931147 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20781977 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20781977 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106810000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105856000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1270000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1489000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59821000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59344000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
48261000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48003000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102261000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99388000 usd
CY2023Q1 us-gaap Revenues
Revenues
30370000 usd
CY2022Q1 us-gaap Revenues
Revenues
26763000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14830000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11396000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
15540000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
15367000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
114000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
248000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
710000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3224000 usd
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3319000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12061000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11816000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
15647000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15892000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-107000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-525000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
484000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
277000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-626000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-830000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-302000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-462000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20853018 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20609372 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20853018 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20609372 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
-282000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
905000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
-63000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
218000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-543000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
319000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48272000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
239000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1047000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
236000 usd
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
4006000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
54000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
687000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
46053000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48003000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
315000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
720000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
243000 usd
CY2023Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
153000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
324000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-219000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
48261000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
114000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
47000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
2955000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
2706000 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
450000 usd
CY2022Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
275000 usd
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
883000 usd
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
228000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
248000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
710000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
720000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1047000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-302000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-462000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
961000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1278000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
823000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-61000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
830000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
50000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
846000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
41000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
313000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1641000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4078000 usd
CY2023Q1 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
3968000 usd
CY2022Q1 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
2931000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
317000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1234000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
966000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3051000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2143000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
13683000 usd
CY2022Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
10696000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
16894000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
12529000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
153000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4006000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
324000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
54000 usd
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
559000 usd
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
511000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3293000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1716000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
91000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
219000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
256000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
405000 usd
CY2023Q1 us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies<div style="margin-top:12pt;padding-right:7.2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. The Company operates in two reportable segments, Integrated Therapy Services (“ITS”) and Durable Medical Equipment Services (“DME Services”).</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 16, 2023.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</span></div>
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q1 us-gaap Revenues
Revenues
30370000 usd
CY2022Q1 us-gaap Revenues
Revenues
26763000 usd
CY2023Q1 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
3054000 usd
CY2022Q4 infu Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
2802000 usd
CY2023Q1 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
12000 usd
CY2022Q4 infu Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
12000 usd
CY2023Q1 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
3042000 usd
CY2022Q4 infu Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
2790000 usd
CY2023Q1 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
100026000 usd
CY2022Q4 infu Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
99163000 usd
CY2023Q1 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
2427000 usd
CY2022Q4 infu Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
2270000 usd
CY2023Q1 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
58979000 usd
CY2022Q4 infu Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
57443000 usd
CY2023Q1 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
38620000 usd
CY2022Q4 infu Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
39450000 usd
CY2023Q1 infu Medical Equipment Net
MedicalEquipmentNet
41662000 usd
CY2022Q4 infu Medical Equipment Net
MedicalEquipmentNet
42240000 usd
CY2023Q1 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2700000 usd
CY2022Q1 infu Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
2400000 usd
CY2023Q1 infu Medical Equipment Increase In Pump Reserve
MedicalEquipmentIncreaseInPumpReserve
100000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9571000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5180000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4391000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9295000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4910000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4385000 usd
CY2022Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
300000 usd
CY2023Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
300000 usd
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2000000 usd
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
52572000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44384000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8188000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
52572000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44136000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8436000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
743000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
990000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
810000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
524000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
471000 usd
CY2023Q1 infu Amortization Expense Year Five And Thereafter
AmortizationExpenseYearFiveAndThereafter
2650000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6188000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
36594000 usd
CY2023Q1 infu Long Term Debt Maturities Repayments Of Principal Year Four And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter
0 usd
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
36594000 usd
CY2023Q1 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0 usd
CY2023Q1 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
208000 usd
CY2023Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
208000 usd
CY2022Q4 infu Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0 usd
CY2022Q4 infu Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
227000 usd
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
227000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36386000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
36386000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
33157000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
33157000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
500000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
300000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20853018 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20609372 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20853018 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20609372 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000 usd
CY2023Q1 infu Share Repurchase Program Cumulative Shares Repurchased
ShareRepurchaseProgramCumulativeSharesRepurchased
6200000 usd
CY2023Q1 infu Share Repurchase Program Cumulative Shares Purchased Shares
ShareRepurchaseProgramCumulativeSharesPurchasedShares
553149 shares
CY2023Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P10Y
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
352000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
329000 usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
76000 usd
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
74000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
428000 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
403000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
449000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
359000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
381000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q1 infu Increases To Right Of Use Assets Resulting From Lease Modifications
IncreasesToRightOfUseAssetsResultingFromLeaseModifications
160000 usd
CY2022Q1 infu Increases To Right Of Use Assets Resulting From Lease Modifications
IncreasesToRightOfUseAssetsResultingFromLeaseModifications
0 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
969000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1235000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1172000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
998000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
826000 usd
CY2023Q1 infu Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2016000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7216000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2383000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4833000 usd
CY2023Q1 infu Lessee Operating Lease Lease Not Yet Commenced Minimum Payment
LesseeOperatingLeaseLeaseNotYetCommencedMinimumPayment
1800000 usd
CY2023Q1 us-gaap Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
P7Y
CY2023Q1 infu Revenues External
RevenuesExternal
30370000 usd
CY2023Q1 infu Revenues Internal
RevenuesInternal
0 usd
CY2023Q1 us-gaap Revenues
Revenues
30370000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
15540000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
15647000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
484000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-302000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-324000 usd
CY2023Q1 us-gaap Assets
Assets
102261000 usd
CY2023Q1 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
3968000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3203000 usd
CY2022Q1 infu Revenues External
RevenuesExternal
26763000 usd
CY2022Q1 infu Revenues Internal
RevenuesInternal
0 usd
CY2022Q1 us-gaap Revenues
Revenues
26763000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
15367000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15892000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
277000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-462000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-368000 usd
CY2022Q1 us-gaap Assets
Assets
98237000 usd
CY2022Q1 infu Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
2931000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3416000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001628280-23-016802-index-headers.html Edgar Link pending
0001628280-23-016802-index.html Edgar Link pending
0001628280-23-016802.txt Edgar Link pending
0001628280-23-016802-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
infu-20230331.htm Edgar Link pending
infu-20230331.xsd Edgar Link pending
infu-20230331xexx10111.htm Edgar Link pending
infu-20230331xexx31111.htm Edgar Link pending
infu-20230331xexx31211.htm Edgar Link pending
infu-20230331xexx32111.htm Edgar Link pending
infu-20230331xexx32211.htm Edgar Link pending
infu-20230331_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
infu-20230331_cal.xml Edgar Link unprocessable
infu-20230331_def.xml Edgar Link unprocessable
infu-20230331_lab.xml Edgar Link unprocessable
infu-20230331_pre.xml Edgar Link unprocessable
infu-20230331_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending